Managing Director & Senior Partner, Global Sector Leader, Biopharmaceuticals
Priya Chandran is a core member of the Health Care and Public Sector practices at Boston Consulting Group. She has been at BCG for 21 years and in that time has worked extensively across all sectors of the health care industry. Priya is a member of the Health Care and Public Sector leadership teams and leads the firm’s Biopharma practice and US Public Sector Health Practice.
Priya is passionate about health care product and system innovation, access and affordability, and driving change. Her work across the public and private sector is focused on these themes.
Priya's biopharma work at BCG has spanned a range of topics across major biopharma companies, including corporate strategy, M&A, discovery and development innovation and productivity, medical affairs and regulatory. She has also partnered across the health care ecosystem on topics of value-based care, market access, affordability, and innovative models for access. Priya has worked across a full range of primary care and specialty TAs as well as a range of modalities including small molecules, vaccines, biologics and CGTs.
In the public sector, Priya has worked across various HHS agencies including CMS, FDA, NIH. She has led programs on topics including COVID response, vaccines and therapeutics, healthcare quality, pandemic preparedness and response, organizational effectiveness and change, data, and analytics.
Prior to joining BCG, Priya was a researcher and project analyst at Ligand Pharmaceuticals in San Diego.
Organizations must build on the momentum from their response to the crisis, delivering better care at lower overall cost and becoming more resilient to future disruptions.
COVID-19 has massive implications for governments, including increased demand for public services and the need to improve resilience. To adapt, leaders must rethink governments’ roles and processes.
The biopharmaceutical industry must respond to a health care community that increasingly demands the delivery not just of drugs and devices but of positive health outcomes.
“Medical affairs” has become increasingly important as physicans’ medical-information needs have grown and become more complex. Here’s how pharma companies can respond to the challenge.